Evoke Pharma Inc (EVOK) Releases Earnings Results, Misses Expectations By $-0.05 EPS

Evoke Pharma Inc (EVOK) reported quarterly earnings results on Wednesday, May-11-2016. The company reported $-0.45 earnings per share for the quarter, missing the analyst consensus estimate by $-0.05. Analysts had a consensus of $-0.40.

Many Wall Street Analysts have commented on Evoke Pharma Inc. Evoke Pharma Inc was Initiated by Northland Capital to “Outperform” on Mar 16, 2016. Company shares were Reiterated by Ascendiant Capital Markets on Mar 14, 2016 to “Buy”, Firm has raised the Price Target to $ 12 from a previous price target of $11 .FBR Capital Resumed Evoke Pharma Inc on Feb 17, 2016 to “Outperform”, Price Target of the shares are set at $17.

Evoke Pharma Inc opened for trading at $4.9883 and hit $5.05 on the upside on Tuesday, eventually ending the session at $5, with a gain of 0.20% or 0.01 points. The heightened volatility saw the trading volume jump to 12,300 shares. Company has a market cap of $36 M.

Evoke Pharma Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001 a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The Company’s lead product candidate EVK-001 is in late stage clinical testing. EVK-001 is a formulation of this drug designed to provide systemic delivery of metoclopramide through intranasal administration. Gastroparesis is a condition of delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis results in food remaining in the stomach for a longer time than normal yielding a variety of symptoms.

Evoke Pharma Inc

Leave a Reply

Evoke Pharma Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Evoke Pharma Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.